Incyte Corp (INCY)

138.08
1.90 1.40
NASDAQ : Health Care
Prev Close 136.16
Open 136.40
Day Low/High 135.01 / 138.75
52 Wk Low/High 55.00 / 133.62
Volume 1.30M
Avg Volume 2.79M
Exchange NASDAQ
Shares Outstanding 204.77M
Market Cap 27.53B
EPS 0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Bulls Won the Day: Cramer's 'Mad Money' Recap (Friday 5/19/17)

Bulls Won the Day: Cramer's 'Mad Money' Recap (Friday 5/19/17)

Ahead of Fed's June meeting, investors will need to start paying close attention to Fed officials and economic data.

Walgreens Boots Alliance, Becton Dickinson, General Mills: 'Mad Money' Lightning Round

Walgreens Boots Alliance, Becton Dickinson, General Mills: 'Mad Money' Lightning Round

Jim Cramer is bullish on Walgreens Boots Alliance, Becton Dickinson, and General Mills.

Going for the Growth: Cramer's 'Mad Money' Recap (Thursday 5/18/17)

Going for the Growth: Cramer's 'Mad Money' Recap (Thursday 5/18/17)

Money managers are piling back into growth stocks without hesitation, says Jim Cramer.

Wall Street Makes a Comeback as Walmart Distracts From Trump Troubles

Wall Street Makes a Comeback as Walmart Distracts From Trump Troubles

Wall Street snaps back to gains on Thursday as positive earnings from Walmart help distract from brewing trouble in Washington, D.C.

Cramer: Let Loose the Growth Hounds

Cramer: Let Loose the Growth Hounds

Day 2 of the selloff brings in an entirely new kind of buyer.

Stocks Add to Gains as Walmart, Health Care Drive Market Comeback

Stocks Add to Gains as Walmart, Health Care Drive Market Comeback

Stocks add to gains on Thursday, coming back from their worst losses in eight months a day earlier, as a positive quarter for Walmart boosts consumer names.

Incyte Shares Vault After 'IDO' Cancer Immunotherapy Combo Data Revealed

Incyte Shares Vault After 'IDO' Cancer Immunotherapy Combo Data Revealed

The new Incyte data revealed ahead of the ASCO meeting in June involve combination therapies with Merck and Bristol-Myers Squibb in multiple types of cancer.

Stocks Turn Higher as Walmart, Health Care Overshadow Trump Trouble

Stocks Turn Higher as Walmart, Health Care Overshadow Trump Trouble

Stocks turn higher as Walmart does the heavy lifting on the Dow and S&P 500, and health care gives a boost to the Nasdaq.

Biotech Movers: Fast Track Designation Sends Sage Shares Higher

Biotech Movers: Fast Track Designation Sends Sage Shares Higher

Sage Therapeutics, Incyte and Shire were among the biotech movers in premarket trading on Thursday.

First Data From Combination Of Epacadostat With Opdivo® (nivolumab) Will Be Highlighted At ASCO 2017

First Data From Combination Of Epacadostat With Opdivo® (nivolumab) Will Be Highlighted At ASCO 2017

Incyte Corporation (Nasdaq:INCY) today announced that the American Society of Clinical Oncology (ASCO) has published Phase 1/2 data from the ongoing ECHO-204 trial evaluating the safety and efficacy of epacadostat, Incyte's...

New Data For Presentation At ASCO 2017 Reinforce Clinical Profile Of Epacadostat In Combination With Keytruda® (pembrolizumab)

New Data For Presentation At ASCO 2017 Reinforce Clinical Profile Of Epacadostat In Combination With Keytruda® (pembrolizumab)

Incyte Corporation (Nasdaq:INCY) today announced the publication of new data from the ongoing ECHO-202 trial, evaluating epacadostat, Incyte's selective IDO1 enzyme inhibitor, in combination with Keytruda ®...

Aduro Biotech, Merck Team on Cancer Drug Trial

Aduro Biotech, Merck Team on Cancer Drug Trial

Aduro Biotech and Merck will team on two separate trials featuring Aduro's CRS-207 and Merck's Keytruda to explore treatments for mesothelioma and gastric cancer.

Analysts' Actions -- Chemours, Incyte, Visteon, Toyota and More

Analysts' Actions -- Chemours, Incyte, Visteon, Toyota and More

Here are Friday's top research calls, including upgrades for Chemours, Incyte and Toyota, and new coverage of Visteon.

Bearish Bets: A Big Biotech, a Computing Legend and Other Stocks That Look Good Short

AMAG, ETM, HYH, CRAY and INCY all recently were downgraded by TheStreet's Quant Ratings.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATRO, BLL, CCE, CSII, EGN, EMR, HCI, IMPV, K, MANT, MLCO, MX, OI, RDS.A, RDS.B, TPRE, USCR, WMC Downgrades: CCO, CLF, GCAP, INCY, KMPR, OMCL, OMI, SHEN, SWIR, UEPS Initiations: ORMP Read on to get TheStreet Quant Ratings' detailed report:

Incyte Reports 2017 First-Quarter Financial Results And Updates On Key Clinical Programs

Incyte Reports 2017 First-Quarter Financial Results And Updates On Key Clinical Programs

Incyte Corporation (Nasdaq: INCY) today reports 2017 first-quarter financial results, highlighting strong revenue growth driven by increased sales of Jakafi ® (ruxolitinib) in the U.

Incyte To Present At Upcoming Investor Conferences

Incyte To Present At Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of May: Bank of America Merrill Lynch 2017 Health Care Conference on Wednesday,...

Sweet Sounds of Numbers; Have Faith: Jim Cramer's View

Sweet Sounds of Numbers; Have Faith: Jim Cramer's View

Cramer shares his views on the preponderance of evidence, and suggests having faith in interational strength.

Incyte's Immuno-oncology And Targeted Therapy Clinical Portfolio To Be Featured In More Than 15 Abstracts At The 2017 ASCO Annual Meeting

Incyte's Immuno-oncology And Targeted Therapy Clinical Portfolio To Be Featured In More Than 15 Abstracts At The 2017 ASCO Annual Meeting

Incyte Corporation (Nasdaq: INCY) announces that more than 15 abstracts highlighting its research and development portfolio in immuno-oncology and targeted therapies will be presented at the upcoming 2017 American Society...

Turnarounds are Tenuous Things: Cramer's 'Mad Money' Recap (Wednesday 04/19/17)

Turnarounds are Tenuous Things: Cramer's 'Mad Money' Recap (Wednesday 04/19/17)

IBM's busted turnaround and difficult transition story shaved more than 50 points off the Dow, says Jim Cramer.

Wells Fargo Among 5 Stocks Insiders Are Loading Up On

Wells Fargo Among 5 Stocks Insiders Are Loading Up On

Insiders at Wells Fargo & Company, Incyte and three other companies have been scooping up shares of their own stock lately.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CUDA, ELS, EMN, FCFS, FSIC, HLF, INCR, PAYC, PBHC, PNR, SABR, SFLY, UTSI, VNOM, WB Downgrades: CUI, IGLD, INCY, MTSC, RUBI, TSEM Initiations: AFI Read on to get TheStreet Quant Ratings' detailed report:

Incyte To Report First Quarter Financial Results

Incyte To Report First Quarter Financial Results

Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 10:00 a.

Wall Street Ends Its Losing Streak As Corporate Earnings Take Focus

Wall Street Ends Its Losing Streak As Corporate Earnings Take Focus

Stocks close in positive territory Monday ahead of a big week for U.S. corporate earnings.

Closing Bell: Stocks End Higher As Corporate Earnings Take Focus

Closing Bell: Stocks End Higher As Corporate Earnings Take Focus

Stocks remained in positive territory breaking a three-day losing streak ahead of U.S. corporate earnings this week, despite mounting tension between North Korea and the U.S.